The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Opthea Limited (CKDXF – Research Report) received a Sell rating and a A$0.05 price target from Bell Potter analyst Thomas Wakim yesterday. The ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...

The first of two of Opthea’s eye disease trials has failed to meet its primary endpoints Hitiq has signed a deal with a key ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...